Ads
related to: depo provera 10 weeks
Search results
Results From The WOW.Com Content Network
Depo-Provera, Depo-SubQ Provera 104, others: AHFS/Drugs.com: depo-provera: Failure rates (first year) Perfect use: 0.2% [37] Typical use: 6% [37] Usage; Duration effect: 3 months (12–14 weeks) Reversibility: 3–18 months: User reminders: Maximum interval is just under 3 months: Clinic review: 12 weeks: Advantages and disadvantages; STI ...
Medroxyprogesterone acetate (brand names Depo-Provera, Provera, Depo-subQ Provera 104) [4] – 150 mg (intramuscularly) or 104 mg (subcutaneously) every 3 months [3] Norethisterone enanthate (brand names NET EN, Noristerat, Norigest, Doryxas) [ 5 ] – 200 mg (intramuscularly) every 2 months [ 3 ]
Depo-Estradiol: Estrogen: IM, SC: 2–10 mg/wk or 5–20 mg every 2 wks ... Depo-SubQ Provera 104: Progestogen: SC: 104 mg every 3 mos Hydroxyprogesterone caproate:
Depot MPA (DMPA) and EC/MPA were developed by Upjohn in the 1960s. [12] [13] DMPA (brand name Depo-Provera) was introduced for use as a progestogen-only injectable contraceptive for the first time outside of the United States in 1969 and was subsequently approved for use in birth control in the United States in 1992.
Depo Provera, the shot: 4 (1 in 25) 0.2 (1 in 500) Progestogen: Injection: 12 weeks: Testosterone injection for male (unapproved, experimental method) [39] Testosterone Undecanoate: 6.1 (1 in 16) 1.1 (1 in 91) Testosterone: Intramuscular Injection: Every 4 weeks: 1999 cervical cap and spermicide (replaced by second generation in 2003) [40] FemCap
Depo-medroxyprogesterone acetate (Depo-Provera, "Depo"). Depo-medroxyprogesterone may have benefits for catamenial epilepsy. Check seizure frequency and consider a shorter dosage interval (e.g., 10 weeks) if seizure frequency increases prior to the next dose (especially if on an enzyme-inducing ASM). Etonogestrel / progesterone implant. Overall ...
CICs are different from progestogen-only injectable contraceptives (POICs), such as depot medroxyprogesterone acetate (DMPA; brand names Depo-Provera, Depo-SubQ Provera 104) and norethisterone enantate (NETE; brand name Noristerat), which are not combined with an estrogen and are given once every two to three months instead of once a month. [2]
Contraceptive Technology reports a typical failure rate of 3% per year for the injection Depo-Provera, and 8% per year for most other user-dependent hormonal methods. [10] While no large studies have been done, it is hoped that newer methods which require less frequent action (such as the patch) will result in higher user compliance and ...